Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.
This malicious action will be reported to the FBI.
mTOR signalling is a major regulator of aging as suppression of this pathway extends lifespan in model organisms. Overactive mTOR
signalling is present in up to 80% of ovarian cancer samples and is associated with poor prognosis.
This study examined the role of mTOR signalling in age-associated changes in ovarian surface epithelium.
These pathological lesions expressed bonafide markers of ovarian cancer precursor lesions, Pax8 and Stathmin 1, and were presented with elevated mTOR signalling. To understand whether overactive mTOR signalling is responsible for the development of these pathological changes, they analysed ovaries of the Pten trangenic mice and found significant reduction in OSE lesions compared to controls.
Collectively, the authors have established the role of mTOR signalling in age-related OSE pathologies and initiation of ovarian cancer.
Dr. Pradeep S. Tanwar
from The School of Biomedical Sciences and Pharmacy in New South Wales Australia said, "Age is a major risk factor for the development of epithelial ovarian cancer.
"
Age is a major risk factor for the development of epithelial ovarian cancer.
Interestingly, a higher number of inclusion cysts are observed in the contralateral ovaries of unilateral OvCa patients and in the ovaries of patients with hereditary predisposition to OvCa compared to the general population.
Assessment of genetic aberrations in ovaries of patients with OvCa, borderline tumours and non-neoplastic disease showed chromosomal alterations in OSE and inclusion cysts.
Moreover, a higher proportion of aneusomic cells were present in the inclusion cysts from OvCa and borderline tumour patients than controls, suggesting that these OSE-derived cysts have the potential to progress to OvCa.
Firstly, mice with germ cell deficiency also exhibit OSE hyperplasia and inclusion cysts, and develop ovarian epithelial tumours with advancing age.
Collectively, these findings suggest that age associated changes in ovary/OSE contribute to the formation of inclusion cysts and consequently, OvCa.
The Tanwar Research Team concluded in their OncotargetResearch Output, "our examination of aged human and mouse ovaries showed hyperactivation of mTOR signalling in OSE pathological lesions. Suppression of mTOR signalling inhibited the development of these lesions in the Ptentg and rapamycin treated mice. Treatment of human OvCa cells with mTOR inhibitors significantly decreased the growth and viability of these cells suggesting that targeting the mTOR pathway might be an effective therapeutic strategy for preventing OvCa.
"
